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Introduction: Drug reaction with eosinophilia and systemic symptoms syndrome is a potentially life-threatening
hypersensitivity reaction with rash, fever, and internal organ involvement, often hepatitis, occurring most commonly
two to eight weeks after initiation of a medication. The present case is an example of severe and potentially
life-threatening hepatitis as a manifestation of drug reaction with eosinophilia and systemic symptoms syndrome.
Case presentation: We report a case of anti-epileptic-induced drug reaction with eosinophilia and systemic
symptoms syndrome in an 18-year-old African-American man who presented with a five-day history of rash,
periorbital and upper extremity edema, hepatitis and fever. Laboratory findings revealed an atypical lymphocytosis,
eosinophilia, and elevated serum transaminases. No drug allergies were reported at the time of presentation, but
phenytoin and levetiracetam therapy had been initiated five weeks prior to hospital admission for new-onset
seizures. Both medications were discontinued on hospital admission, and after three days of high-dose
corticosteroid therapy the patient experienced resolution of both his symptoms and laboratory markers of
inflammation.
Conclusion: Given the significant mortality attributed to drug reaction with eosinophilia and systemic symptoms
syndrome, medical personnel should be aware of the potential for this severe hypersensitivity reaction and should
ensure close follow-up and offer anticipatory guidance when beginning any new medication, particularly
anti-epileptic therapy. Early recognition of drug reaction with eosinophilia and systemic symptoms syndrome and
initiation of appropriate therapy are imperative in limiting morbidity.
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Drug reaction with eosinophilia and systemic symptoms
(DRESS) syndrome, also known as drug-induced hy-
persensitivity syndrome (DIHS), is an under-recognized
and potentially life-threatening hypersensitivity reaction
associated with a variety of medications, many being
anti-epileptics. Patients with DRESS syndrome typically
present with rash, swelling, fever, and systemic manifes-
tations such as a severe transaminitis [1]. In most cases,
a patient’s face, trunk, and upper extremities are affected
by a rash which is at first morbilliform then gradually* Correspondence: jason.fromm@medicine.ufl.edu
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distribution, and reproduction in any mediumtransitions to maculopapular, and finally can progress to
edema of the face, particularly in the periorbital region.
Although rash and eosinophilia are commonly seen in
hypersensitivity reactions, the defining characteristic of
DRESS syndrome is organ dysfunction, most commonly
of the liver, kidneys, heart, or lungs. These patients are
typically found to have started one of a few select medi-
cations in the past two to eight weeks (Table 1) with aro-
matic anti-epileptics being the most commonly
implicated [2-6]. Non-aromatic anti-epileptic medica-
tions such as a topiramate, ethosuximide, and levetirace-
tam were traditionally thought to be safer; however, a
recent case report described DRESS syndrome in a pa-
tient taking only levetiracetam [7]. Although the true in-
cidence is unknown, DRESS syndrome has beentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Drug groups commonly associated with drug
reaction with eosinophilia and systemic symptoms
syndrome
Drug Groups: Specific Examples:
Anticonvulsants phenytoin, carbamazepine,
phenobarbital, lamotrigine, valproate
Antidepressants despiramine, amitriptyline, fluoxetine
Sulfonamides/sulfones dapsone, sulfasalazine, trimethoprim-
sulfamethoxazole
Anti-inflammatories piroxicam, naproxen, diclofenac,
sulindac, ibuprofen
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10,000 new users of anti-epileptic medications and is
more commonly reported in African-American men
[1,8,9]. Vitamin D deficiency has been implicated as a
possible contributor to the pathogenesis of DRESS due
to its protective effects against inflammatory and auto-
immune conditions, and because vitamin D deficiency
occurs more frequently in people with darker skin
phenotypes [10].
DIHS was originally described in 1950 by Chaiken
et al. as a triad of fever, rash, and multi-organ failure
[11]. The acronym DRESS was then put forth by
Bocquet et al. and often includes hepatitis, pericarditis,
interstitial nephritis, or interstitial pneumonitis [1,12].
Isolated elevation of liver transaminases is the most
common laboratory manifestation of hepatitis in DRESS
syndrome. In severe cases it can progress to fulminant
liver failure, occurring in as many as 10% of cases and
accounting for the principle cause of mortality in
patients affected by DRESS syndrome [1]. Although the
pathophysiology of DRESS syndrome remains unknown,
eosinophilic infiltration is probably the mechanism for
involvement of organs such as the liver and kidneys [2].
Prompt recognition and removal of the offending
agent is the key to limiting further hepatic damage,
although hepatitis may significantly worsen even after
discontinuation of the drug and may take months to
resolve completely. Although no randomized-controlled
therapy trials have been done, corticosteroids are utilized
in many reported cases [3-5,8]. No specific therapeutic
regimen or dosing has been shown to be more beneficial
than another, but it is important that therapy is contin-
ued for long enough in order to prevent the possibility
of relapse. The following case report demonstrates the
necessity of prompt recognition and initiation of appro-
priate therapy in preventing the potential sequelae of
DRESS syndrome.Case presentation
An 18-year-old African-American man presented with a
five-day history of pruritic, maculopapular rash with
associated periorbital swelling, fever, and transaminitis.
Five days prior to presentation he noted pruritis and
rash over his extremities, which over the next several
days progressed to his chest, back, and face. He had a
history of seizures that began 35 days prior to this
admission treated with phenytoin extended-release ER
100mg daily and levetiracetam 500mg twice a day. After
investigation, no specific focus or etiology of his seizures
had been identified. He has had decreased verbal and
reading skills since early childhood, but details about his
delivery and early development are unclear because he
was adopted. The patient had no other significant past
medical history, drug allergies, or alcohol use. Review of
systems was positive for non-productive cough, fever,
and tea-colored urine, and negative for chest pain, ab-
dominal pain, shortness of breath, nausea, vomiting,
weight-loss, chills, or any recent altered mental status.
On examination, the patient was febrile to 40.2°C
(104.4°F) with a heart rate of 88 beats/minute, respira-
tory rate of 18, and blood pressure of 110/55mmHg. The
patient was well nourished, well developed, alert and
well oriented, and appeared uncomfortable but not in
distress. A fine exanthematous rash was noted on the
face, upper, and lower extremities in sun-exposed areas
without involvement of the oral mucosa, palms, or soles.
There was profound periorbital edema that prevented
eye-opening. His abdomen was soft and non-distended
with no tenderness, guarding, or hepatosplenomegaly.
No focal deficits were appreciated on neurological exam-
ination. At this point the differential diagnosis included
drug-induced hypersensitivity, erythema multiforme,
toxic epidermal necrolysis, vasculitis, an exanthem due
to viral infection such as Epstein–Barr virus (EBV), cyto-
megalovirus (CMV), and human immunodeficiency virus
(HIV), and auto-immune conditions such as systemic
lupus erythematosus.
Laboratory results revealed a white blood cell count of
7.9 thousand/mm3 (normal from 4.0 to 10.0 thousand/
mm3), with 60% neutrophils, 8.0% lymphocytes, and 4.0%
eosinophils (absolute 0.32 thousand/mm [3]). His free
phenytoin level on admission was 0.4mcg/mL (therapeutic
from 1.0 to 2.0mcg/mL). His basic metabolic panel was
within normal limits. Hepatic function panel revealed an
aspartate aminotransferase of 778U/L (normal from
0 to 37), and alanine aminotransferase (ALT) of 1274U/L
(normal from 0 to 41). Acetaminophen and salicylate
levels were below detectable limits. Evaluation for acute
and chronic hepatitis with serologies was negative for
hepatitis A, B, and C. An extensive workup was performed
including electrocardiogram and echocardiogram which
were negative for abnormalities. EBV, CMV, and HIV
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antinuclear antibodies (ANA). The patient was admitted
to our hospital with a presumptive diagnosis of drug-
induced hypersensitivity. All medications were discontin-
ued and the patient was monitored for signs of clinical
recovery.
On hospital day 1, the patient’s condition worsened
with increased facial swelling and rash extending to his
chest and abdomen. He began to show signs of liver
synthetic dysfunction with an elevated prothombin time
and international normalized ratio as well as an in-
creasing transaminitis. A repeat complete blood count
showed an atypical lymphocytosis and eosinophilia at
8.0%. Because of his deteriorating condition, the patient
was started on dexamethasone 4mg orally four times
daily. On hospital day 2, the patient showed a marked
clinical recovery. Despite improvement in the patient’s
rash, his levels of transaminases continued to climb,
necessitating hepatology consultation to assist with
evaluation for transplantation. On hospital day 3 his
levels of transaminases began to improve, and by day
8 his transaminitis had substantially resolved (Figure 1)
and he was discharged home on prednisone 50mg
to be taken once a day until follow-up with a
hepatologist.
Follow-up five months after discharge revealed that
the patient was doing well with no recurrence of his rash
or other symptoms, no seizures, and normalization of
his serum transaminases. He experienced no flare after
corticosteroid tapering or withdrawal and to date has
not had any hepatic sequelae.Discussion
DRESS syndrome is an often under-diagnosed and under-
recognized severe type IV (delayed type) hypersensitivityFigure 1 Serum measurements of alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) during the patient’s
admission. Normal reference ranges are from 0 to 41U/L for ALT
and from 0 to 37U/L for AST. Day 0 (*) represents the day of
admission and discontinuation of phenytoin. Corticosteroid therapy
was begun on Day 2 (**).reaction that can occur with any medication but most
commonly in response to aromatic anticonvulsants
[1,2,6,9,10,12,13]. Like most severe allergic reactions,
DRESS syndrome involves rash, diffuse swelling, as well as
eosinophilia [1,2,11,14]. The hallmark of DRESS syn-
drome, however, is the presence of systemic manifesta-
tions such as inflammation of the liver, kidneys, heart, or
other organs [1,12,13]. Although no formal diagnostic
criteria have been widely accepted, a Japanese working
group in 2007 established a set of diagnostic guidelines
requiring the following: first, maculopapular rash develop-
ing greater than three weeks after starting a drug; second,
prolonged clinical symptoms two weeks after discontinu-
ation of the causative drug; third, fever greater than 38°C;
fourth, liver abnormalities (including ALT greater than
100U/L); fifth, leukocyte abnormalities (either leukocytosis
greater than 11×109/L, an atypical lymphocytosis, or
eosinophilia greater than 1.5×109/L); sixth, lymphadenop-
athy; and seventh, human herpesvirus 6 (HHV-6) reactiva-
tion [2]. The patient described here met all of these
described criteria for a diagnosis of DRESS. Although he
had no palpable lymphadenopathy, an abdominal com-
puted tomography scan confirmed profound retrope-
ritoneal lymph node enlargement. Finally, a qualitative
deoxyribonucleic acid (DNA) assay revealed the presence
of HHV-6 type B in the patient’s blood, indicating the
reactivation of HHV-6 associated with the patient’s DRESS
syndrome [2,15,16].
Alternatively, Kardaun et al. of the Severe Cutaneous
Adverse Reactions (RegiSCAR) study group published a
scoring system in 2007 which has also been widely used
to evaluate potential cases of DRESS syndrome [14]. The
criteria for this system include: first, fever greater than
38.5°C; second, enlarged lymph nodes; third, eosino-
philia; fourth, atypical lymphocytosis; fifth, skin involve-
ment; sixth, organ involvement; seventh, resolution
greater than 15 days; and eighth, evaluation of other
causes (ANA, blood cultures, serology for hepatitis A
virus, hepatitis B virus, hepatitis C virus, and chlamydia
and/or mycoplasma). Using this scoring system, a final
score of less than two indicates no case, a final score of
between two and three indicates a possible case, a final
score of between four and five indicates a probable case,
and a final score of greater than five indicates a definite
case. The patient in this case report had a score of six
points (one each for lymphadenopathy, eosinophilia,
atypical lymphocytosis, skin rash suggestive of DRESS,
liver involvement, and evaluation of other potential
causes), indicating a ‘definite case’ of DRESS per the
RegiSCAR scoring guidelines.
An important question to consider is which medication
was actually the source of the patient’s reaction, as he had
been started on phenytoin and levetiracetam within days
of each other due to recurring seizures on phenytoin
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response to phenytoin and it has been one of the most
common causative medications, Gómez-Zorrilla et al.
published a case report earlier this year (2012) of a patient
presenting with DRESS syndrome who took no medica-
tions other than levetiracetam [6,7,11]. If the patient were
to again require anticonvulsant therapy, it would be
prudent to avoid use of both phenytoin and levetiracetam,
and to opt instead for an alternative non-aromatic
anticonvulsant.
Prompt recognition of the adverse drug reaction and
discontinuation of offending medication are imperative
steps in limiting the progression of DRESS syndrome.
Pharmacological treatment of DRESS syndrome has to
date not been studied with randomized controlled trials
and instead has been established on the basis of case
reports and retrospective analysis. Systemic corticoste-
roids have become a mainstay of therapy in severe cases
and often produce marked improvement in clinical
symptoms and laboratory measures in just a few days
after the initiation of treatment [3-5,8]. If symptoms
continue to progress despite the use of corticosteroids,
other options include intravenous immunoglobulin
(IVIG) and/or plasmapheresis [6].
The French Society of Dermatology published a report
in 2010 outlining a consensus on therapeutic mana-
gement of DRESS [17]. They recommend the use of
systemic corticosteroids at a dose equivalent to one mg/
kg/day of prednisone in patients with any sign of severity
including: transaminases greater than five times normal,
renal involvement, pneumonia, hemophagocytosis, or
cardiac involvement. They further recommend the use
of IVIG at a dose of two g/kg over five days for a patient
with life-threatening signs such as renal failure or res-
piratory failure. In addition, they propose the use of
steroids in combination with ganciclovir in patients with
signs of severity and confirmation of a major viral reacti-
vation of HHV-6. However, because anti-HHV-6 im-
munoglobulin G titers are not currently widely available
in all hospitals and laboratories, results often take seve-
ral days or weeks to confirm viral reactivation. Because
time is an important factor in the treatment of DRESS,
it is not recommended to delay definitive therapy in
order to confirm a major viral reactivation. Further
study and randomized controlled trials of these and
other potential pharmacologic therapies will be impor-
tant in establishing a standard of care and to improve
understanding of how best to treat patients affected by
DRESS syndrome.
Conclusion
Given the significant mortality attributed to DRESS
syndrome, clinicians should be aware of the potential for
this severe hypersensitivity reaction particularly instarting any new anti-epileptic medication. In patients
presenting with skin rash and systemic abnormalities
after a recent change in medications, physicians should
consider DRESS syndrome as a possible diagnosis and
switch to more aggressive therapy if removal of the
offending agent does not result in clinical improvement.
Further study of potential pharmacological therapies is
warranted given the significant morbidity associated with
DRESS syndrome.
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